Cabinet Barny advised Enterome on the conclusion of a collaborative agreement with Mayo Clinic to develop and commercialize microbiome-based diagnostic tools for nutritional interventions.

Cabinet Barny advised Immutep on the conclusion of a manufacturing agreement by Immutep and Eddingpharm on the product ImmuFact IMP321 (a LAG-31g fusion protein) at WuXi Apptec facilities in China.

Cabinet Barny advised Lysogene on the grant of an exclusive license by RegenX to Lysogene on vectors for the development and commercialization of products to treat Sanfilippo syndrome Type A.

Cabinet Barny advised Domain Therapeutics on the grant to Prexton Therapeutics of an exclusive option to license and develop drugs for Parkinson’s disease.